Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
5
×
san francisco blog main
5
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
cancer
clinical trials
medicare
merck
novartis
pfizer
alnylam pharmaceuticals
biogen
deals
diagnostics
fda
gene therapy
What
patients
5
×
bio
drug
roundup
fda
market
medicine
acquisitions
advantages
ago
albert
alnylam
approve
awaits
bar
becker
biggest
billions
biological
bourla
brings
cancer
ceo
company
crispr
crossed
decades
decision
discovered
dollars
eaton
eisai
expect
fingers
flags
friday
future
gamble
gene
healthcare
Language
unset
unknown
Current search:
biotech
×
patients
×
" san diego top stories "
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision